Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the
Global Non-hodgkin Lymphoma Therapeutics Market
Request Now !
Non-Hodgkin lymphoma (NHL) is a condition where abnormal lymphocytes are produced in the human body. These lymphocytes do not die and keep growing and dividing within the body unless treated. NHL is generally located at lymph nodes, however, if not treated in time then it might spread to the entire lymphatic system.
Factors such as demand for innovative drugs and novel technologies, FDA's approval for chronic lymphocytic leukemia therapy drugs, introduction of promising drugs such as novel small molecule inhibitors and next-generation monoclonal antibodies, and increase in prevalence of NHL drives the market growth. However, high cost of the vaccines used in NHL therapy and side-effects associated with them restrain the market growth. Moreover, introduction of newer biologics in the NHL market, patent expiry of standard drugs in untapped market provide numerous opportunities regarding healthcare in near future.
The non-Hodgkin lymphoma therapeutics market is segmented on the basis of therapy type, cell type, and region. Based on therapy type, it is bifurcated into chemotherapy and targeted therapy. By cell type, it is divided into B-cell lymphomas and T-cell lymphoma. By geography, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
The key players in the market include Bristol Myers Squibb Co., Celgene Corp., Eli Lilly and Co., F. Hoffman La-Roche Ltd., GlaxoSmithKline plc, Accredo Health Group Inc., Baxter International Inc., Bayer AG, Cephalon Inc., and Eisai Pharmaceuticals Inc.
- The study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets.
- Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
- Key players are profiled and their strategies are analyzed thoroughly, which explains the competitive outlook of the global market.
- The report offers a quantitative analysis from 2016 to 2023 to enable the stakeholders to capitalize on the prevailing market opportunities.
- Exhaustive analysis by type helps understand the types of therapy used and the variants that are expected to gain prominence in the future.
Global Non-hodgkin Lymphoma Therapeutics Market Key Segments:
By Type of Therapy
- Targeted Therapy
By Cell type
- B-Cell Lymphomas
- T-Cell Lymphoma
- North America
- Rest of Europe
- South Korea
- Rest of Asia-Pacific
- Saudi Arabia
- South Africa
- Rest of LAMEA
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.4.1. MARKET DYNAMICS
CHAPTER 4 GLOBAL NON-HODGKIN LYMPHOMA THERAPEUTICS MARKET, BY TYPE OF THERAPY
4.1.1. Market size and forecast
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3. TARGETED THERAPY
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
CHAPTER 5 GLOBAL NON-HODGKIN LYMPHOMA THERAPEUTICS MARKET, BY CELL TYPE
5.1.1. Market size and forecast
5.2. B-CELL LYMPHOMAS
5.2.1. Market size and forecast
5.3. T-CELL LYMPHOMAS
5.3.1. Market size and forecast
CHAPTER 6 GLOBAL NON-HODGKIN LYMPHOMA THERAPEUTICS MARKET, BY REGION
6.2. NORTH AMERICA
6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast
184.108.40.206. U.S. market size and forecast
220.127.116.11. Canada market size and forecast
18.104.22.168. Mexico market size and forecast
6.2.4. North America Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy
6.2.5. North America Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type
6.2.6. North America Non-Hodgkin Lymphoma Therapeutics Market, by Treatment
6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast
22.214.171.124. Germany market size and forecast
126.96.36.199. France market size and forecast
188.8.131.52. UK market size and forecast
184.108.40.206. Italy market size and forecast
220.127.116.11. Spain market size and forecast
18.104.22.168. Rest of Europe market size and forecast
6.3.4. Europe Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy
6.3.5. Europe Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type
6.3.6. Europe Non-Hodgkin Lymphoma Therapeutics Market, by Treatment
6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast
22.214.171.124. Japan market size and forecast
126.96.36.199. China market size and forecast
188.8.131.52. Australia market size and forecast
184.108.40.206. India market size and forecast
220.127.116.11. South Korea market size and forecast
18.104.22.168. Taiwan market size and forecast
22.214.171.124. Rest of Asia-Pacific market size and forecast
6.4.4. Asia-Pacific Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy
6.4.5. Asia-Pacific Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type
6.4.6. Asia-Pacific Non-Hodgkin Lymphoma Therapeutics Market, by Treatment
6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast
126.96.36.199. Brazil market size and forecast
188.8.131.52. Turkey market size and forecast
184.108.40.206. Saudi Arabia market size and forecast
220.127.116.11. South Africa market size and forecast
18.104.22.168. Rest of LAMEA market size and forecast
6.5.4. LAMEA Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy
6.5.5. LAMEA Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type
6.5.6. LAMEA Non-Hodgkin Lymphoma Therapeutics Market, by Treatment
CHAPTER 7 COMPANY PROFILES
7.1. BRISTOL MYERS SQUIBB CO.
7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments
7.2. CELGENE CORP.
7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments
7.3. ELI LILLY AND CO.
7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments
7.4. F. HOFFMAN LA-ROCHE LTD.
7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments
7.5. GLAXOSMITHKLINE PLC
7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments
7.6. ACCREDO HEALTH GROUP INC.
7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments
7.7. BAXTER INTERNATIONAL INC.
7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments
7.8. BAYER AG
7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments
7.9. CEPHALON INC.
7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments
7.10. EISAI PHARMACEUTICALS INC.
7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments